Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma

NCT03239392 is registered in ClinicalTrials.gov with Bioniz Therapeutics as lead sponsor.

NCT NCT03239392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03239392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma
Lead sponsor
Bioniz Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
April 1, 2018
Completion date
June 30, 2020
Enrollment
50 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ctcl, lgl leukemia